Journal
BMC CANCER
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12885-023-10501-5
Keywords
Anaphylaxis; Cetuximab; Galactose-alpha-1; 3-galactose (alpha-Gal); Fluoroenzyme-immunoassay; Drug allergy
Categories
Ask authors/readers for more resources
This study compared the performances of an automated Fluoroenzyme-Immunoassay (FEIA) for screening anti-alpha-Gal IgE with a previously validated anti-cetuximab IgE ELISA. The results showed that FEIA had better discrimination of positive and negative patients, higher specificity, and a higher positive likelihood ratio compared to ELISA. The risk of severe HSR following a positive test was higher with FEIA, while the risk following a negative test was similar.
Background The link between immediate hypersensitivity reactions (HSR) following the first cetuximab infusion and the IgE sensitization against anti-galactose-alpha-1,3-galactose (alpha-Gal) is now well-established. An automated Fluoroenzyme-Immunoassay (FEIA) is available and may facilitate the screening of patients with anti-alpha-Gal IgE before treatment. Methods This study aimed to evaluate its performances as compared to a previously validated anti-cetuximab IgE ELISA, using 185 samples from two previously studied cohorts. Results Despite 21.1% of discrepancies between the two techniques, FEIA discriminated better positive patients and similarly negative ones with a >= 0.525 kU(A)/L threshold. Sensitivity was 87.5% for both tests, specificity was better for FEIA (96.3% vs ELISA: 82.1%). FEIA had a higher positive likelihood ratio (23.9 vs ELISA: 4.89) and a similar negative likelihood ratio (0.13 vs ELISA: 0.15). In our population, the risk of severe HSR following a positive test was higher with FEIA (56.7% vs ELISA: 19.6%) and similar following a negative test (0.7% vs ELISA: 0.8%). Conclusion Although the predictive value of the IgE screening before cetuximab infusion remains discussed, this automated commercial test can identify high-risk patients and is suitable for routine use in laboratories. It could help avoiding cetuximab-induced HSR by a systematic anti-alpha-Gal IgE screening before treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available